Induction therapy with GP plus nimotuzumab and sintilimab for nasopharyngeal carcinoma
Part of Cancer clinical trials.
This trial tests a combination of three drugs as a first treatment for people with locally advanced nasopharyngeal cancer. It aims to see if the treatment shrinks tumors before standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with stage III or IVa nasopharyngeal carcinoma (a type of throat cancer).
- You have not had prior treatment for this cancer (like radiation or chemotherapy).
- You have at least one tumor that can be measured on scans.
- You are in good general health (able to perform daily activities).
- Your blood counts, kidney, and liver function are within trial limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—an immunotherapy (sintilimab), a targeted therapy (bevacizumab), and chemotherapy—for patients with high-risk, locally advanced nasopharyngeal cancer that has not spread to distant organs. The goal is to see if adding these drugs to standard chemoradiation improves outcomes.
This trial tests a combination of two drugs—nimotuzumab (a targeted therapy) and TGP (a chemotherapy)—as a first treatment for people whose nasopharyngeal cancer has returned or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new drug combination called GNT given before standard chemoradiation for people with locally advanced nasopharyngeal cancer. It aims to improve treatment outcomes.
This trial tests a combination of three drugs (sintilimab, anlotinib, and chemotherapy) for nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this combination helps slow or shrink the cancer.
This trial tests two different chemotherapy combinations, each given with two extra drugs (one that targets cancer cells and one that boosts your immune system). It's for people with advanced nasopharyngeal cancer who haven't been treated yet, and it aims to see which combination works better.
This trial tests whether adding sintilimab (an immune treatment) to standard chemoradiotherapy can improve outcomes for people with high-risk, locally advanced nasopharyngeal (throat) cancer. It may help your immune system work better against the cancer alongside radiation and chemotherapy.
Hear when a new Locally Advanced Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.